Print  |  Close

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Active: Yes
Cancer Type: Cervical Cancer
Unknown Primary 		NCT ID: NCT06079671
Trial Phases: Phase III Protocol IDs: D7984C00002 (primary)
NCI-2024-05317
165663
2023-504374-38-00
ENGOT-cx19/GEICO
GOG-3092
Eligibility: 15 Years and older, Female Study Type: Treatment
Study Sponsor: AstraZeneca Pharmaceuticals LP
NCI Full Details: http://clinicaltrials.gov/show/NCT06079671

Summary

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global
study to explore the efficacy and safety of volrustomig in women with high-risk LACC
(FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following
platinum-based CCRT.

Objectives

Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive
treatment with Volrustomig or Placebo.

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.